In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Inovio Pharmaceuticals, Inc.. Trade Record

NASDAQ:INO Inovio Pharmaceuticals, Inc. stock gains 13.01% Exit May 30, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart INO May 11, 2017, priceSeries
About Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus. The company's partners and collaborators include MedImmune, LLC, the Wistar Institute, University of Pennsylvania, Defense Advanced Research Projects Agency, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, the National Institutes of Health, HIV Vaccines Trial Network, National Cancer Institute, and U.S. Military HIV Research Program. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Trade Information
Trade Type
LONG
ReliabilityScore™
92.83
Entry Date
May 11, 2017
Entry Price
6.75
Sell Date
May 30, 2017
Sell Price
7.63
Net Gain
13.01%
Hold Time
12 Trading Days